Omega 3 Polyunsaturated Fatty Acids (PUFA) or Magnesium in Obese Polycystic Ovary Syndrome Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

NA

Total Enrollment

123 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-08-31

Study Completion Date

2025-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Polycystic ovary syndrome (PCOS) is the most prevalent endocrine disorder in reproductive age women. PCOS is usually characterized by an excessive androgen production, menstrual irregularities, and polycystic ovaries. Women with PCOS are often obese and have a varying degree of insulin resistance (IR). Weight reduction constitutes the initial treatment for these patients. Metformin has proven to be useful in IR and is frequently used in PCOS. However metformin use may be accompanied by gastrointestinal discomfort, and a high abandon rate. Other therapeutic alternatives such as magnesium and polyunsaturated fatty acids have been used in other IR states and may be useful in PCOS. The aim of this study is to asses the efficacy of these alternatives in obese PCOS patients.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Light Fasting Diet and Magnesium in Polycystic Ovary Syndrome (PCOS)

NCT07322120

Polycystic Ovary Syndrome

NOT_YET_RECRUITING NA

n-3 Polyunsaturated Fatty Acids (PUFA) Supplementation in Young Women With Polycystic Ovary Syndrome (PCOS)

NCT01189669

Polycystic Ovary Syndrome

COMPLETED NA

Transcriptomic Profile of Adipose Tissue Following n-3 Polyunsaturated Fatty Acid (PUFA) Supplementation

NCT01195155

Polycystic Ovary Syndrome

COMPLETED NA

Dietary Fish Oil Intervention in Polycystic Ovary Syndrome (PCOS)

NCT04116203

Polycystic Ovary Syndrome Lipid Metabolism Disorders

COMPLETED PHASE1

Effect of Magnesium Supplementation on Polycystic Ovary Syndrome

NCT02178150

Polycystic Ovary Syndrome

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Polycystic Ovary Syndrome (PCOS)

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Polycystic Ovary Syndrome Obesity

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

The study is open label. No blindness for participant or investigator is used

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Metformin

Metformin 850mg twice a day for six months

Group Type ACTIVE_COMPARATOR